Free shipping on all orders over $ 500
Tofersen (BIIB067) is an antisense oligonucleotide that mediates RNase H-dependent degradation of superoxide dismutase 1 (SOD1) mRNA to reduce SOD1 protein synthesis. Tofersen can be used in amyotrophic lateral sclerosis (ALS) research.
| Molecular Weight | 7128.00 |
| CAS Number | 2088232-70-4 |
| Solubility (25°C) | Water ≥ 60 mg/mL |
| Storage | -20°C, dry, sealed |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[1] Timothy M Miller, et al. N Engl J Med. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
[2] Johannes Dorst, et al. Curr Opin Neurol. Clinical studies in amyotrophic lateral sclerosis
[4] Daisuke Ito. Ann Neurol. Promise of Nucleic Acid Therapeutics for Amyotrophic Lateral Sclerosis
| Related DNA/RNA Synthesis Products |
|---|
| PR-104
PR-104 is a novel hypoxia-activated DNA cross-linking agent with marked activity against human tumor xenografts, both as monotherapy and combined with radiotherapy and chemotherapy. |
| D-I03
D-I03 is a selective RAD52 inhibitor with a Kd of 25.8 µM. D-I03 specifically inhibits RAD52-dependent single-strand annealing (SSA) and D-loop formation with IC50s of 5 µM and 8 µM, respectively. |
| Bractoppin
Bractoppin is a potent and selective inhibitor of phosphopeptide recognition by the human BRCA1 tandem(t) BRCT domain with IC50 of 74 nM. Bractoppin diminishes BRCA1 recruitment to DNA breaks, in turn suppressing damage-induced G2 arrest and assembly of the recombinase, RAD51. |
| Plitidepsin
Plitidepsin (Aplidine) is a potent anticancer compound targeting eEF1A2 (KD=80 nM). Plitidepsin has antiviral activity, and the IC90 of inhibiting SARS-CoV-2 is 0.88 nM. Plitidepsin is commonly used in multiple myeloma and advanced cancer research and has potential for COVID-19 research. |
| ART812
ART812 is an orally effective DNA polymerase Polθ inhibitor with an IC50 value of 7.6 nM. ART812 had an IC50 value of 240 nM for cell-based microhomologous mediated end-junction (MMEJ). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.
